Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
|Articles|January 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 1
- Volume 17
- Issue 1
Sunesis and MMRC collaborate to study SNS-032 in myeloma
Sunesis and MMRC collaborate to study SNS-032 in myeloma
Advertisement
SOUTH SAN FRANCISCO, California-Sunesis Pharmaceuticals, Inc. and the Multiple Myeloma Research Consortium (MMRC) have entered into a collaboration to evaluate Sunesis' SNS-032 for the treatment of multiple myeloma. SNS-032 is a potent, selective inhibitor of cyclin-dependent kinases (CDKs) 2, 7, and 9 that inhibits both cell cycle progression and transcription.
Articles in this issue
almost 19 years ago
New tobacco product alert: Camel Snus is on the loosealmost 19 years ago
Blueberry punch not quite a 'knock out' blowalmost 19 years ago
Texas voters listen to Lancealmost 19 years ago
Cellectar opens manufacturing facility for radiolabeled CLR1404almost 19 years ago
High cost of breast MRI screening appears to be justifiedalmost 19 years ago
Broccoli Sprouts Extract Might Lower Bladder Cancer Riskalmost 19 years ago
Xeloda/Ixempra Effective in Resistant Triple-Negative Caalmost 19 years ago
Statins during RT may lower risk of prostate ca relapseAdvertisement
Related to this article
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acid Reducers, Drug-Drug Interactions, and Setting Expectations for Response
2
Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care
3
How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy
4
How to Work With a Patient Who Declines Cancer Treatment
5